Australia markets open in 9 hours

Alexion Pharmaceuticals, Inc. (ALXN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
155.01+0.54 (+0.35%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 534.08B
Enterprise value 333.99B
Trailing P/E 56.99
Forward P/E 110.77
PEG ratio (5-yr expected) 11.32
Price/sales (ttm)5.61
Price/book (mrq)2.92
Enterprise value/revenue 35.60
Enterprise value/EBITDA 710.66

Trading information

Stock price history

Beta (5Y monthly) 1.27
52-week change 360.57%
S&P500 52-week change 349.51%
52-week high 3162.60
52-week low 394.82
50-day moving average 3152.62
200-day moving average 3140.60

Share statistics

Avg vol (3-month) 32.61M
Avg vol (10-day) 31.53M
Shares outstanding 5219.85M
Implied shares outstanding 6N/A
Float 218.83M
% held by insiders 10.46%
% held by institutions 191.30%
Shares short (14 Mar 2021) 47.8M
Short ratio (14 Mar 2021) 42.82
Short % of float (14 Mar 2021) 43.70%
Short % of shares outstanding (14 Mar 2021) 43.55%
Shares short (prior month 11 Feb 2021) 47.9M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 322 May 2011

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020


Profit margin 9.94%
Operating margin (ttm)47.47%

Management effectiveness

Return on assets (ttm)10.10%
Return on equity (ttm)5.26%

Income statement

Revenue (ttm)6.07B
Revenue per share (ttm)27.58
Quarterly revenue growth (yoy)15.00%
Gross profit (ttm)5.52B
Net income avi to common (ttm)603.4M
Diluted EPS (ttm)2.72
Quarterly earnings growth (yoy)-39.70%

Balance sheet

Total cash (mrq)3B
Total cash per share (mrq)13.65
Total debt (mrq)2.93B
Total debt/equity (mrq)25.16
Current ratio (mrq)3.59
Book value per share (mrq)53.08

Cash flow statement

Operating cash flow (ttm)3B
Levered free cash flow (ttm)2.11B